Analysts Issue Forecasts for LXEO Q1 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.80) per share for the quarter. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.79) EPS.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09.

LXEO has been the topic of several other research reports. HC Wainwright reissued a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday. Leerink Partners dropped their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Finally, Chardan Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, March 25th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $22.80.

Remove Ads

Lexeo Therapeutics Stock Performance

LXEO stock traded down $0.01 during trading on Wednesday, reaching $4.10. 322,531 shares of the company's stock were exchanged, compared to its average volume of 345,505. The firm has a market cap of $136.11 million, a PE ratio of -1.30 and a beta of 3.85. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.50. The company's fifty day moving average price is $4.05 and its 200-day moving average price is $6.56.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Allostery Investments LP acquired a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics during the 4th quarter valued at $46,000. BNP Paribas Financial Markets increased its stake in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter worth $69,000. Finally, SG Americas Securities LLC purchased a new position in Lexeo Therapeutics in the fourth quarter valued at about $72,000. Hedge funds and other institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.